In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
|Videos|August 5, 2021
The Modern HIV PrEP Options and Care Teams Are Evolving
Author(s)Kevin Kunzmann
Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.
Advertisement
The goals for
In the first segment of an interview with Contagion, David Koren, MPH, BCPS, Clinical Pharmacist Specialist in ID & HIV at Temple University Hospital, discussed the current administration strategies and research in place to combat a national decrease in PrEP prescriptions.
What’s needed, Koren stressed, is a prioritization of direct HIV-risk prescription access.
“In order for that to be able to happen, we just need more members of the care team,” Koren explained. “And I’d like to say that really has evolved to include pharmacists in a really meaningful way lately.”
The initiation of prescribing at the pharmacy level leads to the concept of “de-medicalizing PrEP,” Koren explained, and allowing for community-level access.
Along the way, new research is seeking to innovate the availability of PrEP options to include longer dose durations and different methods of delivery—details which emphasize the desire for patient-specific interests.
“Choice is king, especially when we’re asking people to take a medication for an infection they don’t even have,” Koren said. “People are going to come to the table with their own wants and needs.”
Advertisement
Related to this article
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Advertisement
Advertisement